SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-005751
Filing Date
2021-01-11
Accepted
2021-01-11 07:00:54
Documents
14
Period of Report
2021-01-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d107122d8k.htm   iXBRL 8-K 26526
2 EX-99.1 d107122dex991.htm EX-99.1 16920
6 GRAPHIC g107122g0109075514971.jpg GRAPHIC 3504
  Complete submission text file 0001193125-21-005751.txt   174199

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tvtx-20210111.xsd EX-101.SCH 3093
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvtx-20210111_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvtx-20210111_pre.xml EX-101.PRE 10968
7 EXTRACTED XBRL INSTANCE DOCUMENT d107122d8k_htm.xml XML 3254
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 21519075
SIC: 2834 Pharmaceutical Preparations